Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00791323 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Ketorolac 0.4% in Prostaglandin Suppression
A Phase 4 study of Inflammation, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00791323: Completed Phase 4 study of Inflammation, sponsored by Allergan.
NCT00791323 is a Phase 4 study of Inflammation that has completed, run by Allergan. The registered enrollment target is 9 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00791323, a Phase 4 study of Inflammation, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy
Primary Outcome
The mean level of PGE2 (a naturally occurring prostaglandin E2 in the eye that can cause inflammation and other complications) in the aqueous humor (the thin, watery fluid in the eye) 2 days following peripheral iridotomy (ocular surgery).
Conditions Studied
Interventions
- DRUG Ketorolac 0.4%
- DRUG Lubricating Eye Drop
Study Locations (1)
Texas
- - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-08 |
| Phase | Phase 4 |
What the finished NCT00791323 record still lists
NCT00791323 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Ketorolac 0.4% is the first listed.
NCT00791323 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00791323 about?
NCT00791323 is a clinical study titled "Efficacy of Ketorolac 0.4% in Prostaglandin Suppression". A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy
What is the current status of trial NCT00791323?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2008-11. Estimated completion is 2009-08.
What conditions does trial NCT00791323 study?
This clinical trial studies the following conditions: Inflammation.
What interventions are being tested in trial NCT00791323?
The interventions under investigation include: Ketorolac 0.4% (DRUG), Lubricating Eye Drop (DRUG).
Who is sponsoring clinical trial NCT00791323?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00791323 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00791323's enrollment target sits among peer trials
9 132nd of 132 higher than 1 of 132 other Inflammation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Skin Barrier Function and Inflammation in Aging: The BIA Study
RECRUITING · Phase 4
-
Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis
COMPLETED · Phase 4
-
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
COMPLETED · Phase 4
-
Impact of Ascorbic Acid on Post-Cardiothoracic Surgery Inflammation
COMPLETED · Phase 4
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia